30 Years of Biotherapeutics Development-What Have We Learned?

16Citations
Citations of this article
100Readers
Mendeley users who have this article in their library.

Abstract

Since the birth of biotechnology, hundreds of biotherapeutics have been developed and approved by the US Food and Drug Administration (FDA) for human use. These novel medicines not only bring significant benefit to patients but also represent precision tools to interrogate human disease biology. Accordingly, much has been learned from the successes and failures of hundreds of high-quality clinical trials. In this review, we discuss general and broadly applicable themes that have emerged from this collective experience. We base our discussion on insights gained from exploring some of the most important target classes, including interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), IL-6, IL-12/23, IL-17, IL-4/13, IL-5, immunoglobulin E (IgE), integrins and B cells. We also describe current challenges and speculate about how emerging technological capabilities may enable the discovery and development of the next generation of biotherapeutics.

Cite

CITATION STYLE

APA

Ghilardi, N., Pappu, R., Arron, J. R., & Chan, A. C. (2020, April 26). 30 Years of Biotherapeutics Development-What Have We Learned? Annual Review of Immunology. Annual Reviews Inc. https://doi.org/10.1146/annurev-immunol-101619-031510

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free